Core Insights - Tempus AI (TEM) is enhancing its leadership in precision medicine through impactful research initiatives and clinical validations, particularly in AI-driven diagnostics for cancer treatment decisions [1] Research and Clinical Validation - In January 2026, TEM's Immune Profile Score (IPS) was shown to more accurately predict outcomes for patients receiving immune checkpoint inhibitors (ICIs) compared to conventional biomarkers like tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 [2] - A study published in September 2025 in JCO Precision Oncology validated the clinical utility of the PurIST algorithmic diagnostic, providing the largest real-world evidence to date for guiding first-line treatment decisions in advanced pancreatic ductal adenocarcinoma (PDAC) [3] - In April 2025, TEM published a study in the Journal of Molecular Diagnostics supporting the xF+ non-invasive technique for detecting actionable variants, identifying clinically relevant biomarkers, and monitoring disease progression [4] Peer Updates - Illumina (ILMN) reported in November 2025 that whole-genome sequencing (WGS) reveals more about the genetic causes of common diseases than older methods, with rare variants identified through WGS accounting for much of the missing heritability in complex diseases [5] - Myriad Genetics (MYGN) presented new data at the 2026 ASCO-GU conference supporting its various cancer tests, highlighting its expanding role in cancer care [6] Stock Performance - Over the past year, Tempus' shares have increased by 15.8%, contrasting with a 25.3% decline in the industry, while the S&P 500 composite has improved by 24.2% [7] Valuation Metrics - TEM currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 5.67X, compared to the industry median of 5.34X, indicating an expensive valuation [10] - The loss per share estimate for 2025 has widened from 42 cents to 56 cents over the past 30 days [11]

Core Insights - Myriad Genetics is presenting new data at the 2026 ASCO-GU conference that emphasizes its expanding role in cancer care through its molecular diagnostic tests, including the Precise MRD Test, Prolaris Prostate Cancer Prognostic Test, and MyRisk Hereditary Cancer Tests [1][8] Group 1: Precise MRD Test - The Precise MRD Test demonstrates high sensitivity in detecting molecular residual disease in genitourinary cancers, with detection events occurring at ctDNA concentrations below 100 parts per million [2] - Early evidence suggests a correlation between ctDNA levels and clinical outcomes, indicating the test's potential to provide clinically significant information [2] Group 2: Prolaris Prostate Cancer Prognostic Test - A robust meta-analysis of 14 studies involving over 8,000 patients supports the prognostic power of the Prolaris Test, showing significant prognostic value for distant metastasis and prostate-cancer specific mortality [3] - Prolaris is found to be prognostic beyond conventional risk categories based solely on clinical factors, aiding in initial treatment decisions [3] Group 3: MyRisk Hereditary Cancer Test - Data presented on the MyRisk Test indicate that germline positivity rates do not significantly differ across Gleason score and NCCN risk groups, suggesting that germline testing should not be limited to high-risk patients [4] - The findings may broaden the scope of individuals who could benefit from genetic testing in localized prostate cancer [4] Group 4: Conference Details - Myriad Genetics will exhibit at the ASCO-GU conference from February 26-28, 2026, at the Moscone West Conference Center in San Francisco, showcasing its latest research and findings [5][6]